Some GLP-1s are tied to a reduced risk of worsening symptoms of anxiety, depression, substance use disorder, and self-harm.

AN ORAL PCSK9 inhibitor significantly reduced low-density lipoprotein cholesterol (LDL-C) compared with existing oral ...

Scientists have unveiled a novel injectable acid-tolerant bioadhesive for large gastric perforation. Discover more.

Robot-assisted radical prostatectomy outcomes are comparable across ages. Find out why older patients can safely undergo RARP. Read more.

Discover how AI improves seasonal allergic rhinitis diagnosis and supports personalised treatment decisions. Read more.

Pregnant women living with HIV face a global tuberculosis incidence rate almost six times that of their non-pregnant ...

YOGURT can be introduced from 6 months, offering nutrients and live cultures that support infant health.

Children with Mycoplasma pneumoniae infection may face higher plastic bronchitis risk when fever and NLR rise. Read more.

Stopping RAS inhibitors after eGFR decline may raise risk of kidney failure and death. Learn more about this new study.

Eli Lilly won FDA approval on 1 April 2026 for a once-daily oral GLP-1, orforglipron. Read more about the drug and its ...

Hospital crisis decision-making may protect preparedness but sideline other services during emergencies. Read more.

Hospital-acquired pneumonia remains a major ICU threat as new diagnostics and tailored treatment strategies reshape care.